Filing Flows

Filing Flows › Companies › Lineage Cell Therapeutics › Cash flow

Lineage Cell Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.4M in Q2 2026 · −$24.4M over twelve months

Operating cash flow−$7.2M
Capital spending−$108K
Free cash flow−$7.4M
Cash / net income-4.7×

Analysis

In Q2 2026, Lineage Cell Therapeutics generated −$7.2M of operating cash flow and spent $108K on capital projects, leaving free cash flow of −$7.4M. That is $1.8M less than in Q2 2025 (−$5.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$23.8M; the largest uses were operating cash flow ($23.8M), other investing ($13.1M), capital spending ($574K); besides operations, cash came from other financing ($30.9M), shares issued ($1.5M); the cash balance fell by $4.9M.

Operating cash flow was −$7.2M against net income of $1.5M — -4.7× profit, less cash than reported earnings, worth checking against working capital. The largest differences: stock-based pay +$1.6M, deferred revenue −$698K, prepaid and other assets +$654K.

Free cash flow

Lineage Cell Therapeutics: free cash flow by quarterLineage Cell Therapeutics: free cash flow by quarter−$5.9MQ3 2024−$6.7MQ4 2024−$5.0MQ1 2025−$5.6MQ2 2025−$3.6MQ3 2025−$5.3MQ4 2025−$8.1MQ1 2026−$7.4MQ2 2026
Operating cash flow less capital spending.
Lineage Cell Therapeutics: operating cash flow against capital spendingLineage Cell Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$5.8M$112KQ3 2024−$6.3M$365KQ4 2024−$4.9M$97KQ1 2025−$5.5M$14KQ2 2025−$3.6M$12KQ3 2025−$4.9M$399KQ4 2025−$8.1M$55KQ1 2026−$7.2M$108KQ2 2026
Latest (Q2 2026): Operating cash flow −$7.2M, Capital spending $108K.

Capital allocation, year by year

Lineage Cell Therapeutics: where the cash came from (up) and went (down), by fiscal yearLineage Cell Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$23.6MFY2021: Net borrowing −$20KFY2021: Shares issued $38.1MFY2021: Asset sales $14KFY2021: Capital spending −$340K$38.1MFY2021FY2022: Operating cash flow $1.1MFY2022: Net borrowing −$32KFY2022: Shares issued $796KFY2022: Capital spending −$413K$1.9MFY2022FY2023: Operating cash flow −$28.6MFY2023: Net borrowing −$54KFY2023: Shares issued $6.7MFY2023: Capital spending −$674K$6.7MFY2023FY2024: Operating cash flow −$23.1MFY2024: Net borrowing −$54KFY2024: Shares issued $229KFY2024: Capital spending −$565K$229KFY2024FY2025: Operating cash flow −$18.9MFY2025: Net borrowing −$59KFY2025: Shares issued $1.2MFY2025: Capital spending −$522K$1.2MFY2025
Over these 5 years operating cash flow totalled −$93.1M; the largest uses were operating cash flow ($94.1M) and capital spending ($2.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$50.8M
Debtnone
Net cash$50.8M
Cash runway2.1 years

Lineage Cell Therapeutics is burning cash: its operations consume cash, a free cash flow of −$24.4M a year at the current rate against $50.8M of cash and investments: a runway of about 2.1 years before any new financing.

Where the cash came from and went

Lineage Cell Therapeutics: sources (+) and uses (−) of cash, Q2 2026Lineage Cell Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$7.2MOther financing$4.5MOther investing$4.1MCash drawn (+) / kept (−)−$1.4MExchange rates$259KCapital spending−$108KNet borrowing (+) / repaid (−)−$9KShares issued$6K
Lineage Cell Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Lineage Cell Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$30.9MOperating cash flow−$23.8MOther investing−$13.1MCash drawn (+) / kept (−)$4.9MShares issued$1.5MCapital spending−$574KExchange rates$430KNet borrowing (+) / repaid (−)−$54KTaxes on employees’ shares−$41K

From profit to cash

Lineage Cell Therapeutics: net income to operating cash flow, Q2 2026Lineage Cell Therapeutics: net income to operating cash flow, Q2 2026Net income$1.5MDepreciation & amortization$187KStock-based pay$1.6MGains on disposals$19KReceivables$19KPayables−$341KDeferred revenue−$698KPrepaid and other assets$654KOperating cash flow−$7.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 202525—3961-3936
Q4 202417—828-812
Q3 20248—4826-4819

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$7.2M−$108K−$9K$6K−$1.4M−$7.4M
Q1 2026−$8.1M−$55K−$14K$227K$4.8M−$8.1M
Q4 2025−$4.9M−$399K−$15K$763K−$347K−$5.3M
Q3 2025−$3.6M−$12K−$16K$487K$1.8M−$3.6M
Q2 2025−$5.5M−$14K−$14K—$5.6M−$5.6M
Q1 2025−$4.9M−$97K−$14K—−$2.0M−$5.0M
Q4 2024−$6.3M−$365K−$14K—−$18.0M−$6.7M
Q3 2024−$5.8M−$112K−$13K$10K$1.9M−$5.9M

Lineage Cell Therapeutics: income statement and cash flow

Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%. The chart follows the revenue to costs, profit and cash.

Lineage Cell Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.